Recent research from UCL has brought new insights into the ever-evolving battle between human immunity and SARS-CoV-2, mainly focusing on the latest variants, such as BA.4 and BA.5.
Published in Nature Microbiology, this study delves into the evolution of eight omicron variants and how they interact with human immunity post-vaccination.
The study reveals a fascinating evolutionary journey of the SARS-CoV-2 virus. When vaccines were introduced, early omicron variants like BA.1 lost their ability to overcome human innate immunity effectively.
However, newer variants like BA.5 and XBB have regained this capability. This finding suggests a common evolutionary strategy in the virus, which is crucial for ongoing pathogen surveillance.
Since the onset of the COVID-19 pandemic, various SARS-CoV-2 variants, including alpha, delta, and omicron, have emerged, each with unique characteristics.
Previous research showed that the alpha and delta variants had evolved mechanisms to bypass human innate immunity, our body’s first line of defense against infections.
They achieved this by disrupting cellular signals in the airways, which normally trigger an antiviral immune response.
This disruption allows the virus time to establish in the body and potentially overcome the adaptive immunity developed from prior infection or vaccination.
Interestingly, the evolution of the omicron variants was influenced by the pre-existing immunity in the population due to vaccination and previous infections.
These vaccines generate antibodies targeting the virus’s spike protein, which protects cells through a process called neutralization.
In the UCL and University of Glasgow study, researchers used cell models to observe how different omicron sub-variants interact with human hosts.
They found that while early omicron variants like BA.1 and BA.2 were less adept at evading innate immunity compared to alpha or delta, recent omicron variants have learned to bypass this immunity in a similar manner.
Dr. Ann-Kathrin Reuschl, the first author of the study, noted that the early omicron subvariants’ relative inability to evade innate immunity might have contributed to reports of reduced disease severity.
The more recent omicrons have increased production of innate immune antagonist proteins, such as nucleocapsid and Orf6, similar to alpha and delta variants.
Professor Greg Towers, a senior author, explained that this study aids in understanding how a pandemic coronavirus adapts to human hosts and suggests future viral evolution pathways.
It shows the virus’s strategy to fine-tune immune escape, altering its spike and protein levels for maximizing human-to-human transmission.
The study’s findings elucidate why SARS-CoV-2 continues to infect people despite widespread immunity from vaccines and previous infections. It underscores the importance of protective measures like wearing FFP3 masks to prevent infection from airborne virus particles.
Professor Clare Jolly, another senior author, highlighted the unique opportunity presented by SARS-CoV-2 to observe in real-time how a virus evolves to overcome human defenses.
This knowledge is invaluable in predicting the behavior of potential pandemic viruses and assessing the risks posed by emerging viruses or new variants.
The research concludes that while the ability to avoid innate immunity may be less crucial than evading neutralizing antibodies for SARS-CoV-2 transmission, it remains a significant aspect of the virus’s survival strategy.
The findings emphasize the need for continued monitoring of the virus as it evolves.
This study provides critical insights into the ongoing battle between SARS-CoV-2 and human immunity. Understanding how the virus adapts and evolves to overcome our defenses not only helps in managing the current pandemic but also prepares us for future viral threats.
The evolution of SARS-CoV-2 variants underlines the importance of continuous research and surveillance in the field of infectious diseases, especially as we face the challenges of new variants and their impact on global health.
In summary, this research sheds light on the dynamic and complex nature of viral evolution in the face of human immunity.
The findings from UCL’s study contribute significantly to our understanding of SARS-CoV-2, offering valuable insights for developing more effective strategies to combat not only the current pandemic but also future infectious diseases.
For more information about COVID, please see recent studies about new evidence on rare blood clots after COVID-19 vaccination, and results showing zinc could help reduce COVID-19 infection risk.
The research findings can be found in Nature Microbiology.
Copyright © 2024 Knowridge Science Report. All rights reserved.